Recent Price Movement and Market Context
On 8 December 2025, Brooks Laboratories’ stock touched an intraday low of Rs.95.55, representing a fall of 3.92% on the day. This decline contributed to an overall loss of 3.02% for the session. The stock has been on a downward trajectory for eight consecutive trading days, resulting in a cumulative return of -8.84% during this period. This performance notably underperformed the Pharmaceuticals & Biotechnology sector by 2.41% on the same day.
The stock’s current price is well below its moving averages, trading lower than the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This technical positioning indicates a sustained weakness in price momentum over both short and long-term horizons.
In contrast, the broader market, represented by the Sensex, showed a modest decline of 0.38% on the day, closing at 85,389.67 points. The Sensex remains close to its 52-week high of 86,159.02, trading approximately 0.9% below that peak. The benchmark index continues to trade above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a generally bullish trend in the wider market.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
Long-Term Performance and Valuation Metrics
Over the past year, Brooks Laboratories’ stock has recorded a return of -30.44%, a stark contrast to the Sensex’s 4.52% gain during the same period. The stock’s 52-week high was Rs.202.80, indicating a substantial reduction in value from its peak.
From a fundamental perspective, the company’s long-term financial indicators reveal several areas of concern. The average Return on Equity (ROE) stands at 2.42%, which is relatively modest for the Pharmaceuticals & Biotechnology sector. Net sales have shown a compound annual growth rate of 4.36% over the last five years, suggesting limited expansion in revenue generation.
Debt servicing capacity appears constrained, with an average EBIT to interest ratio of -3.69, indicating challenges in covering interest expenses from operating earnings. Despite this, the company’s most recent ROE was 12.1%, and it carries a Price to Book Value ratio of 2.5, which is considered elevated relative to its historical valuations and peer group.
While the stock is trading at a discount compared to its peers’ average historical valuations, it has consistently underperformed the BSE500 index over the last three annual periods. This trend highlights ongoing difficulties in matching broader market returns.
Recent Financial Results and Operational Data
Brooks Laboratories has reported positive results for the last four consecutive quarters. The company’s net sales for the latest six months reached Rs.48.96 crores, reflecting a growth rate of 26.45%. Profit before tax excluding other income for the most recent quarter was Rs.7.59 crores, showing a significant increase of 2563.2% compared to the previous four-quarter average.
Operating cash flow for the year was recorded at Rs.2.63 crores, the highest level reported in recent periods. Net sales growth of 4.06% was noted in the latest quarter, contributing to the positive quarterly results declared in September 2025.
Despite these encouraging quarterly figures, the stock’s price performance has not mirrored this improvement, as the downward trend in share price continues.
Considering Brooks Laboratories ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Shareholding and Sectoral Positioning
The majority shareholding in Brooks Laboratories is held by promoters, maintaining a concentrated ownership structure. The company operates within the Pharmaceuticals & Biotechnology sector, which has experienced varied performance across its constituents in recent months.
While the broader sector has seen mixed results, Brooks Laboratories’ stock has notably lagged behind sector averages, reflecting specific challenges faced by the company relative to its peers.
Summary of Key Price and Performance Indicators
To summarise, Brooks Laboratories’ stock has reached a fresh 52-week low of Rs.95.55, following a series of declines over the past eight trading sessions. The stock’s current valuation metrics and long-term financial indicators point to subdued growth and profitability compared to sector benchmarks. Despite recent quarterly improvements in sales and profitability, the share price has not reflected these developments, continuing to trade below all major moving averages.
The broader market environment remains relatively stable, with the Sensex maintaining a position near its 52-week high and trading above key moving averages. This divergence highlights the specific pressures affecting Brooks Laboratories within the Pharmaceuticals & Biotechnology sector.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
